EML4-ALK mutations in lung cancer that confer resistance to ALK inhibitors. - Wikidata - awgldk - TriplyDB

EML4-ALK mutations in lung cancer that confer resistance to ALK inhibitors.

EML4-ALK mutations in lung cancer that confer resistance to ALK inhibitors.

http://www.wikidata.org/entity/Q27851590

about

Crystal structure of EML1 reveals the basis for Hsp90 dependence of oncogenic EML4-ALK by disruption of an atypical β-propeller domain MED12 controls the response to multiple cancer drugs through regulation of TGF-β receptor signaling ALK mutations confer differential oncogenic activation and sensitivity to ALK inhibition therapy in neuroblastoma Molecular biology of lung cancer Clinical use of crizotinib for the treatment of non-small cell lung cancer Crizotinib resistance: implications for therapeutic strategies The role of the ALK receptor in cancer biology Tackling ALK in non-small cell lung cancer: the role of novel inhibitors Tyrosine Kinase Receptor Landscape in Lung Cancer: Therapeutical Implications Non-Invasive Methods to Monitor Mechanisms of Resistance to Tyrosine Kinase Inhibitors in Non-Small-Cell Lung Cancer: Where Do We Stand?Overcoming resistance to first/second generation epidermal growth factor receptor tyrosine kinase inhibitors and ALK inhibitors in oncogene-addicted advanced non-small cell lung cancer New treatment options for ALK+ advanced non-small-cell lung cancer: critical appraisal of ceritinib The steady progress of targeted therapies, promising advances for lung cancer Recent Advances in Targetable Therapeutics in Metastatic Non-Squamous NSCLC Molecular mechanisms that underpin EML4-ALK driven cancers and their response to targeted drugs ALK inhibitors in non-small cell lung cancer: the latest evidence and developments ALK and ROS1 as targeted therapy paradigms and clinical implications to overcome crizotinib resistance Personalized treatment options for ALK-positive metastatic non-small-cell lung cancer: potential role for Ceritinib Crizotinib as a personalized alternative for targeted anaplastic lymphoma kinase rearrangement in previously treated patients with non-small-cell lung cancer The distinctive nature of adenocarcinoma of the lung Progress of EGFR-TKI and ALK/ROS1 inhibitors in advanced non-small cell lung cancer Treating patients with ALK-positive non-small cell lung cancer: latest evidence and management strategy Overcoming resistance to targeted therapies in NSCLC: current approaches and clinical application ALK-positive non-small cell lung cancer: mechanisms of resistance and emerging treatment options Combating acquired resistance to tyrosine kinase inhibitors in lung cancer Molecular testing guideline for selection of lung cancer patients for EGFR and ALK tyrosine kinase inhibitors: guideline from the College of American Pathologists, International Association for the Study of Lung Cancer, and Association for Molecular Ligand-triggered resistance to molecular targeted drugs in lung cancer: roles of hepatocyte growth factor and epidermal growth factor receptor ligands ALK and ROS1 as a joint target for the treatment of lung cancer: a review Emerging importance of ALK in neuroblastoma Tumour heterogeneity and the evolution of polyclonal drug resistance Targeting EML4-ALK driven non-small cell lung cancer (NSCLC)Targeted therapies in CLL: mechanisms of resistance and strategies for management Research Progress of HGF/c-MET Inhibitor in the Treatment of Non-small Cell Lung Cancer Review of the current targeted therapies for non-small-cell lung cancer Targeted therapies in development for non-small cell lung cancer Overview of ALK and ROS1 Rearranged Lung Cancer ALK kinase domain mutations in primary anaplastic large cell lymphoma: consequences on NPM-ALK activity and sensitivity to tyrosine kinase inhibitors CIViC database The R1275Q Neuroblastoma Mutant and Certain ATP-competitive Inhibitors Stabilize Alternative Activation Loop Conformations of Anaplastic Lymphoma Kinase Acquired Resistance to Crizotinib from a Mutation in CD74 – ROS1

P2860

0b745f2875e69ac57664fa88dc06e41d0d000e36 d547b87ca425b418d9c1e9c0a2cdcdbda744a1c8 df022116834ddbc4853be15ca5a781efd6d860d2

P248

Q24294276-C94D807F-ECE8-4AF9-8BC5-24C36BFBFA2B Q24304423-9335F4B0-1D00-4E42-8E34-B636190A413F Q24310296-E33AA4D1-0B0D-4D8C-A6A0-7668889F692C Q24606677-FE37094C-1E1D-420B-81A0-B34A17654061 Q24630466-3357AA97-2FA4-4117-88C9-69CC9C8EDD46 Q26738381-A7A6558F-2113-41E6-A4C1-7F563E2A8F9E Q26738384-97BDDB2A-D8E7-4D20-B161-5773D6419E6D Q26740329-193CFDFC-5318-4023-8824-FE0C7F64FA11 Q26741318-076D7179-62C3-4D7A-BF49-70E92538EDFF Q26741814-EC2D6382-927B-42EC-8E8F-A8EFBC47FD73 Q26745427-068DBE14-7F90-422F-AF07-AACA32837CCD Q26746230-958E6142-F4C2-4DC9-B095-ED18C21D739D Q26746895-0A3C78EF-1073-4412-85DF-8A4FB8E69A0C Q26747276-C6E883F6-BA30-41C1-9E3B-CD1D10B2F9C9 Q26769659-0C1E61BB-8779-4774-BC2B-BD491234AC29 Q26769879-62789C40-37D8-4734-A3BD-DE09C681A6AA Q26775347-6C660A21-788F-4299-A731-1AFEE56FD966 Q26775817-3D85285F-3AEA-423E-998F-C8E263E249F5 Q26778500-6D322158-D54D-4E10-A2B9-E2D8221B7C6F Q26781159-73F848AC-4378-43DD-86B2-8E400F2A5459 Q26784298-EC044FED-AD25-4F07-862F-3FEB1964AAFA Q26795555-734AEC84-643F-4F6A-B6EC-DEE9206C48DE Q26795556-61D9CA9B-674D-4D99-A1F3-70E2BEF9FFB5 Q26820845-7A6E6947-B99C-4408-84A8-12ACE9CA04F2 Q26824877-9B20675E-7D8C-4EEE-A22F-B48126F69EF0 Q26828860-DADB2BA2-F421-422E-8BE2-618378EEC947 Q26829104-668DE6E2-715F-42C9-B161-A1BF019E0D6F Q26851392-A8DCB4AD-3BD6-4C09-9634-0112B56025A5 Q26858819-853ED124-1DA5-4A69-9575-7351A96ADA7F Q26866803-3982C382-84CF-4C8E-AE0D-21D7D671625B Q27002155-7F026576-14CD-4EAD-A587-70DF602D8C92 Q27002528-6B026605-9786-4282-8C0A-16A92F0DF1F9 Q27006349-66A8225D-01B5-4E31-A8AE-52288A8B07A5 Q27015079-6E1F0AE1-C68E-479F-A93C-0DA7C38A79EE Q27022852-1239B25E-53C4-4190-8D26-4A5E879BA640 Q27024602-EA63B69D-1BED-4E0A-A6F6-9841999BDDB8 Q27310990-7E3956BB-9729-4C2F-92E3-DAED84E78095 Q27612411-C8C3AEF5-EE55-434B-B0D9-05AC62BDCEC1 Q27671787-27888FCD-C18E-4B3D-B2FF-4DCB42BE75CE Q27678436-672BBE80-323D-4508-B36A-41550E22C732

P2860

EML4-ALK mutations in lung cancer that confer resistance to ALK inhibitors.

http://www.wikidata.org/entity/Q27851590

description

2010 nî lūn-bûn

@nan

2010 թուականի Հոկտեմբերին հրատարակուած գիտական յօդուած

@hyw

2010 թվականի հոտեմբերին հրատարակված գիտական հոդված

@hy

2010年の論文

@ja

2010年論文

@yue

2010年論文

@zh-hant

2010年論文

@zh-hk

2010年論文

@zh-mo

2010年論文

@zh-tw

2010年论文

@wuu

name

EML4-ALK mutations in lung cancer that confer resistance to ALK inhibitors.

@ast

EML4-ALK mutations in lung cancer that confer resistance to ALK inhibitors.

@en

EML4-ALK mutations in lung cancer that confer resistance to ALK inhibitors.

@nl

type

label

EML4-ALK mutations in lung cancer that confer resistance to ALK inhibitors.

@ast

EML4-ALK mutations in lung cancer that confer resistance to ALK inhibitors.

@en

EML4-ALK mutations in lung cancer that confer resistance to ALK inhibitors.

@nl

prefLabel

EML4-ALK mutations in lung cancer that confer resistance to ALK inhibitors.

@ast

EML4-ALK mutations in lung cancer that confer resistance to ALK inhibitors.

@en

EML4-ALK mutations in lung cancer that confer resistance to ALK inhibitors.

@nl

P1433

Q27851590-2416E16A-ADD9-4D8A-897C-20E90CA7381C

P1476

Q27851590-E205AE23-2775-4FD3-A5E7-4814167AFA96

P2093

Q27851590-26F702BA-27BE-46FA-A13B-0BF930031271

Q27851590-5B728ED2-DCBB-4599-9222-29EE36977990

Q27851590-652DB454-733E-4223-A3F0-CD487396EF36

Q27851590-661FB2D7-2F31-49AE-A115-0C19692D4580

Q27851590-B33C70BE-A443-45EF-AEE3-0E0ACFC82C36

Q27851590-B813621E-B0AA-49B6-B74D-250B7134DBD3

Q27851590-D4B67F78-80AE-41E4-AF75-95F93C7F44C6

Q27851590-D4CEC262-AB5B-45EC-98BE-A0E03B79F958

Q27851590-DCD7D8AE-5933-4463-9213-807865F57C9E

Q27851590-EB249B7E-F300-4C8D-B206-46D62324E6AC

P304

Q27851590-4E45C4DF-45AA-4741-83CC-564D198A7140

P31

Q27851590-7745DABD-8B71-4DC5-AE62-AA1735F7A4A1

P3181

Q27851590-C9DFC642-CDA7-447E-BA74-55AFFA2E5C66

P356

Q27851590-B1A5382C-AE93-496B-8E17-0FD18184CD2A

P407

Q27851590-F82338E3-243E-4536-A8CA-BD29D2AF2E37

P433

Q27851590-D4E56D2C-C8B7-4690-BA62-6A0EF8362D5A

P478

Q27851590-2724504A-1871-4404-85D1-D32838CB977A

P50

Q27851590-07A23561-D645-4AA5-89F5-FEBB5095CF87

Q27851590-8AAAB32E-CB46-4F0E-A2B5-E1749C103DDD

Q27851590-B0F1E44A-4780-41DA-9F7C-47831FC6B2CA

P577

Q27851590-8E0965F7-C724-43D5-9F25-78997150A916

P698

Q27851590-02A588E4-592D-49FF-8C4E-49C4F2AA69FE

P3181

P356

P1433

The New England Journal of Medicine

P1476

EML4-ALK mutations in lung cancer that confer resistance to ALK inhibitors

@en

P2093

ALK Lung Cancer Study Group

http://www.w3.org/2001/XMLSchema#string

Hideki Kimura

http://www.w3.org/2001/XMLSchema#string

Hidenori Haruta

http://www.w3.org/2001/XMLSchema#string

Hiroyuki Mano

http://www.w3.org/2001/XMLSchema#string

Junpei Takashima

http://www.w3.org/2001/XMLSchema#string

Manabu Soda

http://www.w3.org/2001/XMLSchema#string

Takahiro Nakajima

http://www.w3.org/2001/XMLSchema#string

Toru Hamada

http://www.w3.org/2001/XMLSchema#string

Toshihide Ueno

http://www.w3.org/2001/XMLSchema#string

Yoshihiro Yamashita

http://www.w3.org/2001/XMLSchema#string

P304

1734-1739

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P3181

455546

http://www.w3.org/2001/XMLSchema#string

P356

10.1056/NEJMOA1007478

http://www.w3.org/2001/XMLSchema#string

P407

P433

18

http://www.w3.org/2001/XMLSchema#string

P478

363

http://www.w3.org/2001/XMLSchema#string

P50

Tetsuya Mitsudomi

P577

2010-10-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

20979473

http://www.w3.org/2001/XMLSchema#string